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In Algeria, few data is available concerning the distribution of pneumococcal serotypes
and respective antibiotic resistance for the current pre-vaccination period, which is
a public health concern. We identified the most frequent Streptococcus pneumoniae
serogroup/types implicated in invasive pneumococcal disease (IPD; n= 80) and carriage
(n = 138) in Algerian children younger than 5 years old. Serogroup/types of 78 IPD
isolates were identified by capsular typing using a sequential multiplex PCR. Overall,
serotypes 14, 19F, 6B, 23F, 18C, 1, 5, 7F, 19A, and 3 (55% of PCV7 serotypes, 71.3%
of PCV10, and 90% of PCV13) were identified. Additionally, 7.5% of the non-vaccine
serotypes 6C, 9N/L, 20, 24F, 35B, and 35F, were observed. In the case of S. pneumoniae
asymptomatic children carriers, the most common serogroup/types were 6B, 14, 19F,
23F, 4, 9V/A, 1, 19A, 6A, and 3 (42.7% of PCV7 serotypes, 44.2% of PCV10, and
58% of PCV13). For 6.1% of the cases co-colonization was detected. Serotypes 14,
1, 5, and 19A were more implicated in IPD (p < 0.01), whereas serotype 6A was
exclusively isolated from carriers (p < 0.01). Deaths associated with IPD were related
to serotypes 19A, 14, 18C, and one non-typeable isolate. Among IPD related to vaccine
serotypes, the rates of penicillin non-susceptible isolates were higher in no meningitis
cases (80%) than in meningitis (66.7%), with serotypes 14, 19A, 19F, and 23F presenting
the highest MIC levels (>2µg/ml). Resistance to cefotaxime was higher in isolates from
meningitis (40.5%); however, resistance to erythromycin and co-trimoxazole (>40%)
was more pronounced in no-meningeal forms. Overall, our results showed that PCV13
conjugate vaccine would cover up to 90% of the circulating isolates associated with IPD
in Algeria, highlighting the importance of monitoring the frequency of S. pneumoniae
serogroups/types during pre- and post-vaccination periods.
Keywords: pneumococci serotype, antibiotic susceptibility, invasive disease, pneumococcal carriage, children,
vaccine, Algeria
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INTRODUCTION
Streptococcus pneumoniae remains the leading cause of bacterial
infection among children worldwide, being the most common
cause of bacterial pneumonia, and an important cause of
meningitis and bacteremia. Approximately 800,000 deaths per
year occur among children as a result of pneumococcal infection
(Johnson et al., 2010). The management of pneumococcal
infections has been aggravated by the rapid worldwide increase
of resistance to penicillin and other antibiotics, mostly related to
the misuse of these drugs in respiratory pathogens (Song et al.,
2012; Ginsburg et al., 2013).
Despite the diversity of capsular types, comprising at least 98
distinct serotypes, only some variants are associated with invasive
pneumococcal disease (IPD; Caierão et al., 2014; Richter et al.,
2014).
Pneumococcal disease is frequently preceded by
asymptomatic nasopharyngeal colonization, which can be
quite high in early childhood (Bogaert et al., 2004; Miernyk
et al., 2011; Satzke et al., 2013). It is generally agreed that most
serotypes recovered from IPD are also frequently identified in
colonized healthy children (Bogaert et al., 2004; Dias and Caniça,
2007). However, serotype prevalence can change according to
age, geography, time, and antibiotic resistance, among other
factors (Finland and Barnes, 1977; Hausdorff et al., 2005; Ingels
et al., 2012). IPD has also been related to recent respiratory viral
infection (Weinberger et al., 2014).
In some countries, the use of effective pneumococcal
conjugate vaccines (PCVs) during infancy have contributed to
reduce morbidity and mortality associated to IPD, as well as
nasopharyngeal colonization by vaccine serotypes (Ghaffar et al.,
2004; Millar et al., 2006; Tan, 2012). Despite the availability of
these vaccines, pneumococcal infections remain a global problem
due to the replacement of vaccine by non-vaccine serotypes,
mostly associated with the emergence of multidrug resistant
serotypes, such as the serotype 19A (Dias and Caniça, 2007;
Dagan et al., 2009; Richter et al., 2014). Thus, due to the
widespread phenomena of serotype replacement, PCVs have
been substituted by higher valence pneumococcal vaccines (from
PCV7 and PCV10 to PCV13) across the world, according with
the recommendations of the Centers for Disease Control and
Prevention (CDC, 2013).
The monitoring of antibiotic resistance trends and serotype
distribution in the pre- and post-vaccination periods is essential
to assess the dynamic change of epidemiology. This way, the
impact of vaccines and antibiotic use control programmes should
be evaluated across countries.
In this study, we analyzed the frequency of serotypes
associated to IPD and S. pneumoniae asymptomatic carriage
among children younger than 5 years old in Algeria, before the
introduction of the pneumococcal vaccine, and correlated the
isolates antibiotic susceptibility with vaccine serotypes .
MATERIALS AND METHODS
Bacterial Isolates
An overall of 218 S. pneumoniae isolates recovered from children
<5 years old were collected and studied regarding the serotype.
Briefly, 80 IPD isolates [children <1 year old (n = 44), 1–2
years old (n = 20), and 3–5 years old (n = 16)] were collected
between the 1st January 2010 and the 31st December 2014. The
isolates were recovered from routine microbiological cultures at
Laboratory of Clinical Microbiology, at CHU Mustapha Bacha
(LCM/CHU), Algiers, Algeria, and at cooperation laboratories in
the north (n = 50), west (n = 12), south (n = 2), and northeast
(n = 16) regions of the country that sent samples and/or isolates
to LCM/CHU. Isolates were included if they were obtained from
consecutive blood, and cerebrospinal, pleural, peritoneal, ascitic,
bone, and joint fluids from patients with symptoms compatible
with IPD. Only one isolate per patient was considered .
In addition, all nasopharyngeal cultures (n = 130) recovered
at LCM/CHU between 2011 and in 2012, from asymptomatic
children <5 years old were also included for serotyping
evaluation. Each age group of <1 year, 1–2 years, and 3–5 years
included 91, 20, and 27 S. pneumoniae isolates, respectively. Only
one isolate per child was considered, except for eight cultures
corresponding to carriers co-colonized with two pneumococcal
serogroups/types (in a total of 138 isolates). Authorization for
carriage study was approved by “The Direction de la Santé et de
la Population de la Wilaya d’Alger,” in Algeria.
Culture of sterile body fluids and nasopharyngeal samples at
LCM/CHUwas carried out by standard protocols. Pneumococcal
isolates were identified using classic microbiological tests:
colony morphology, optochin susceptibility, and bile solubility
(Figure 1). Thirty seven S. pneumoniae isolates expressing
different serogroups/types (1, 3, 4, 5, 6B, 6C, 7F, 7C, 8, 9V, 9N,
10A, 10F, 11A, 12F, 13, 14, 15A, 15B, 16F, 17F, 18C, 19F, 19A,
20, 21, 22F, 23A, 23B, 23F, 24F, 31, 33F, 34, 35A, 35B, and 35F),
belonging to the collection of the National Reference Laboratory
of Antibiotic Resistances and Healthcare Associated Infections,
at National Institute of Health in Portugal, were also used as
controls for serotype identification, as previously (Ziane et al.,
2015).
DNA Extraction and Multiplex PCRs
To extract DNA from clinical and control S. pneumoniae isolates,
several colonies were picked from the culture plates. DNA was
extracted by the heat lysis method and stored at −20◦C until
further analysis. The serogroups, and whenever possible the
serotypes, of 80 S. pneumoniae from IPD and of 138 recovered in
asymptomatic carriers were determined by sequential multiplex
groups (SMGs), as previously described (Ziane et al., 2015;
Figure 1).
Quellung Serotyping
In addition to multiplex PCR (Ziane et al., 2015),
serogroups/types of all the 80 invasive isolates were determined
at LCM/CHU by Quellung reaction with specific type antiserum
[Statens-Serum Institute]. Concerning the isolates recovered
from carriers, only those determined as serotype 6A/B or as
non-typeable by the multiplex PCR method, were characterized
by Quellung reaction (Figure 1).
PCR Detection of Autolysin (lytA) Gene
A primer pair 5′-TCCAGCCTGTAGCCATTTCG-3′ and 5′-
GCGGTTGAACTGATTGAAAG-3′ that specifically targeted a
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FIGURE 1 | Multiplex PCR scheme used in capsular typing of S. pneumoniae isolates from Algeria, and general scheme proposed for usual
pneumococcal serotyping.
472 bp internal region of the autolysin (lytA) gene was
used to the identification of cps-negative S. pneumoniae. The
amplification conditions were: initial denaturation at 94◦C
for 5 min., followed by 30 cycles of denaturation at 94◦C
for 30 s, annealing at 56◦C for 30 s and extension at
72◦C for 30 s, and a final extension at 72◦C for 5 min.
Positive and negative controls were included in each PCR
reaction.
Antibiotic Susceptibility Testing
Susceptibility testing of 72 IPD vaccine serotype isolates and
of 8 IPD non-vaccine serotype was carried out by an agar
disk diffusion method for four antibiotics (erythromycin,
clindamycin, co-trimoxazole, tetracycline), and minimal
inhibitory concentration (MIC) was determined using E-test
method (AB Biodisk) for four β-lactam antibiotics (penicillin,
amoxicillin, cefotaxime, and imipenem). Testing conditions and
susceptibility interpretation followed the standards proposed by
the Clinical and Laboratory Standards Institute (CLSI, 2014).
S. pneumoniae ATCC 49619 was used as the quality control
strain.
Statistical Analysis
OpenEpi software, version 3.03a (Dean et al., 2015), was
used for statistical analysis. Fisher exact test was used
to assess differences between IPD and carriers groups.
One-tail P ≤ 0.05 were considered to be statistically
significant.
RESULTS
IPD Serogroup/Types
Between 2010 and 2014, a total of 207 episodes of IPD were
registered at LCM/CHU. Among those, 80 (38.6%) corresponded
to children <5 years old and were retained for this study. These
80 IPD cases (Figure 2) comprised 56.3% of occurrences in males
and 43.7% in females, with 64 cases (80%) being reported to
infants (≤2 years old). Overall, the serotypes were identified in
78 isolates, while two were non-typeable (Table 1).
Forty-eight (60%) of the total IPD episodes included cases of
meningitis [of which 62.5% (30/48) were in infants <1 year old],
while 40% (32/80) comprised cases of nonmeningitis [56.3% of
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FIGURE 2 | Serogroup/types distribution and age groups in children under 5 years old according to clinical presentations of invasive pneumococcal
disease (IPD) episodes. Abdominal infections, S. pneumoniae was isolated from ascitic and peritoneal fluids; NT, non-typeable.
which were pleuropneumonia (18/32), including 55.5% (10/18)
in infants from 1 to 2 of age; Figure 2]. The most frequent
serotypes implicated in IPD in this study, which accounted for
87.5% (70/80) of the tested isolates, were in decreasing frequency
(Figure 3): 14, 19A, 19F, and 1 (from 0 to 5 years old), 5 (from 0
to 2 years old), 6B (from 0 to 5 years old), 3 (from <1 year old),
and 23F (from<1 year, and from 3 to 5 years old). Serotypes 14, 1,
19A, 19F, 5, 3, and 6B were the most common inmeningitis cases.
However, serotypes 14, 19A, 5, and 6B were also implicated in
pleuropneumonia, and 19A, 19F, and 14 in bacteremia (Figure 2).
Deaths caused by S. pneumoniae infection were noticed in 7
IPD cases (7/80, 8.8%) associated with meningitis (6/7, 85.7%),
and pneumonia (1/7, 14.3%). Serotypes 19A and 14 were cause
of death in 3 (42.8%), and 2 (28.6%) cases, respectively. The two
remaining death cases were caused by serotype 18C, and one
non-typeable isolate.
A total of 44 pneumococcal isolates expressed the serotypes
included in PCV7, which would reflect the coverage of 55%
(44/80) (Figure 4; Table 1). The coverage of PCV10 would be
of 71.3% (57/80), because there were 13 isolates expressing
serotypes 1 (6/57, 10.5%), 5 (6/57, 10.5%), and 7F (1/57, 1.8%).
The coverage of PCV13 would reach up to 90% (72/80) (Figure 4,
Table 1). All PCVs would cover the three age groups included in
the study. Non-vaccine serogroup/types were expressed in 7.5%
(6/80) with one isolate of each: 6C/D, 9N/L, 20, 24F, 35B, and 35F.
Serogroup/Types Characterization of
Nasopharyngeal Isolates
The serogroup/type of 138 isolates, identified in 130
nasopharyngeal cultures from colonized children <5 years
old, was determined by multiplex PCR method, using the same
scheme as for IPD isolates (Figure 1): 117 (83.6%) S. pneumoniae
were characterized at the serogroup/type level [101 (86.3%)
children carried a single serogroup/type, whereas eight children
(8/132, 6.1%) were co-colonized with pneumococci belonging to
two different serogroup/types]. Furthermore, of the 18 isolates
that remained non-typeable by multiplex PCR reactions, 3 were
assigned to serogroup/type 15, 19A, and 20 by the Quellung
reaction (Table 1). Serogroup 6A/B was differentiated by
Quellung reaction into serotype 6B (n = 16) and serotype 6A
(n= 13).
The most common serogroup/type was 6 (n = 31) [divided
in 6A (n = 13), 6B (n = 16) (both included in PCV13 and
PCV7, respectively), and 6C/D (n = 2)]; it was followed by
serogroup/type 14 (n = 13), 19F (n = 12), and 23F (n = 11;
Figure 4; Table 1). All these four serogroup/types were identified
in the three age groups defined: <1 year, 1–2 years, and 3–
5 years (Figure 3). The remaining conjugate vaccine serotypes
identified in asymptomatic children carriers of S. pneumoniae
included 19A (n = 5), 4 (n = 4), 9V/A (n = 3), 1 (n = 2),
and 3 (n = 1). Non-conjugate vaccine serotypes accounted for
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TABLE 1 | S. pneumoniae conjugate vaccines PCV7, PCV10, and PCV13 and non conjugate vaccine serotypes implicated in IPD cases and in
nasopharyngeal carriage, according to the age groups.
Serotypes/Age(years) IPD Nasopharyngeal carriage Global total P-valuea
<1 1–2 3–5 Total <1 1–2 3–5 Total
PCV7 SEROTYPES
4 1 1 2 4 4 0.161
6 B 4 1 1 6 12 2 2 16 22 0.245
9V/A 1 2 3 3 0.256
14 13 6 7 26 4 4 5 13 39 <0.01
18 C 1 1 1 0.364
19 F 2 4 2 8 6 5 1 12 20 0.449
23 F 1 2 3 8 1 2 11 14 0.182
Subtotal 20 12 12 44 31 14 14 59 103 0.045
ADDITIONAL PCV10 SEROTYPES
1 4 1 1 6 2 2 8 0.028
5 5 1 6 6 <0.01
7 F 1 1 1 0.364
Subtotal 10 2 1 13 2 2 15 <0.01
ADDITIONAL PCV13 SEROTYPES
3 3 3 1 1 4 0.138
6A 11 1 1 13 13 <0.01
19 A 6 4 2 12 5b 5b 17 <0.01
Subtotal 9 4 2 15 16 1 2 19 34 0.203
NON CONJUGATE VACCINE SEROTYPES
6 C 1 1 1 1 2 3 0.700
8 1 1 1 0.636
9 N/L 1 1 1 0.364
10A 1 1 1 0.636
11A/D 3 3 3 0.256
15 1c 1c 1 0.636
15 A/F 3 1 2 6 6 0.064
15B/C 5 5 5 0.116
16F 1 1 1 0.636
17F 1 1 1 0.636
20 1 1 1c 1c 2 0.700
23A 1 1 2 2 0.404
23B 3 1 4 4 0.161
24 F 1 1 1 1 2 3 0.700
33F/A/37 1 1 1 0.636
34 4 1 5 5 0.116
35 B 1 1 3 1 4 5 0.401
35 F 1 1 1 0.364
Subtotal 4 1 1 6 29 2 9 40 46 <0.01
Total Typeable 43 19 16 78 78 17 25 120 198 <0.01
Non typeable 1 1 2 13 3 2 18 20d <0.01
Global Total 44 20 16 80 91 20 27 138 218
aOne-tail P ≤ 0.05 were considered to be statistically significant.
bFour isolates were serotyped by Multiplex PCR and one was serotyped by Quellung reaction.
c Isolates serotyped only by Quellung reaction.
dThree Multiplex PCR non-typeable isolates were serotyped only by Quellung reaction (serotypes 19Ab, 15c, and 20c ).
29% (40/138), identified by both PCR (n = 38) and Quellung
reaction (n= 2). These serotypes were mostly identified as 15A/F,
15B/C, 34, 23B, 35B, and 11A/D. Globally, the section of the
study that included the carrier patients allowed the identification
of 120 isolates at serogroup/type level, and the evaluation of 18
non-typeable isolates.
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FIGURE 3 | Distribution of serogroup/types and pneumococcal conjugate vaccine (PCV) coverage for invasive pneumococcal disease (IPD) (n = 80)
and nasopharyngeal (n = 140) isolates in children aged 5 years and less, shown by age group. NT, non-typeable.
Overall, 4.1% (09/218) of the isolates lacked the cpsA
gene. However, the presence of the lytA gene confirmed
the identification of S. pneumoniae specie. In addition, the
sequential multiplex PCR scheme (Figure 1) used in our study
demonstrated a specific identification of each serogroup/type in
90.8% (198/218) of the isolates analyzed: among the 80 IPD and
the 138 nasopharyngeal S. pneumoniae isolates, 97.5% (78/80)
and 86.9% (120/138) were positively serotyped by sequential
multiplex PCR, respectively (p < 0.01; Table 1).
Antibiotic Susceptibility and Vaccine
Serotype
Among S. pneumoniae vaccine serotypes (n = 72) from
meningitis (n = 39) we identified 66.7% isolates penicillin non-
susceptible (MIC ≥ 0.12 µg/ml) with 25.6% showing high level
of resistance (MIC 2–4 µg/ml; Table 2). Isolates non-susceptible
to cefotaxime and imipenem corresponded to 40.5 and 43.2%,
respectively. However, high level of resistance was noticed for
imipenem only in 5.4% isolates.
From no meningitis infections (n = 25), 80% of the isolates
were penicillin non-susceptible with 12% of high level of
resistance (MIC = 4–8 µg/ml). Intermediate resistance to
amoxicillin and cefotaxime was 9.1 and 8.3%, respectively. High
level of resistance to amoxicillin was observed in 4.5% isolates
(MIC 8 µg/ml).
Non-susceptibility to erythromycin, clindamycin, co-
trimoxazole, and tetracycline occurred in lower frequencies in
isolates from meningitis (42.5, 40, 53.8, and 27.2%, respectively)
than in isolates from no meningitis infections (74.1, 66.7, 75, and
46.2%, respectively).
High level of resistance for vaccine serotypes was observed in
serotypes 14, 19A, 19F, and 23F. Overall, the vaccine serotypes
14, 19A, 19F, 23F, 6B, and 5 presented higher rates of resistance
(90–100%) than the eight non-vaccine serotypes (6C, 9N, 20, 24F,
35B, 35F, non-typable; p < 0.05; data not shown).
DISCUSSION
S. pneumoniae remains the leading cause of bacterial infection
among children worldwide, including numerous cases of
invasive disease associated high morbidity and mortality rates
(Harboe et al., 2010; Adegbola et al., 2014). The pneumococcal
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FIGURE 4 | Rate of serogroup/type cumulative coverage (C %) in each conjugate vaccine (PCV7, PCV10, PCV13) for S. pneumoniae recovered from
invasive pneumococcal disease (IPD) and asymptomatic carriers less than 5 years old, from Algeria. NT, non-typeable.
epidemiology regarding capsular types and antibiotic resistance
varies geographically and temporally in terms of origin of
the isolates (infections or carriage), clinical presentation,
pathogenicity (Hausdorff et al., 2005; Harboe et al., 2010;
Ingels et al., 2012; Geno et al., 2015), and the methods used
for serotyping (Turner et al., 2011; Song et al., 2012; Geno
et al., 2015). Although antibiotic susceptibility and serotype
data remains insufficient in many countries such as Algeria,
its collection and evaluation is essential for the treatment of
pneumococcal infections and for the usage of conjugate vaccines
(Ramdani-Bouguessa and Rahal, 2003; Tali-Maamar et al., 2012;
Ziane et al., 2012; Ramdani-Bouguessa et al., 2015).
Thus, the main goal of this study was to analyze the
frequency of serotypes associated to IPD and S. pneumoniae
asymptomatic carriage in Algeria, in children<5 years old before
the introduction of the pneumococcal vaccine. To accomplish
our purpose, we used the more recent IPD samples studied in
the country (Ramdani-Bouguessa and Rahal, 2003; Tali-Maamar
et al., 2012; Ziane et al., 2012; Ramdani-Bouguessa et al., 2015). It
is worth mentioning that a molecular approach was here applied
for the first time to isolates recovered in this country in the
context of a monitoring survey of S. pneumoniae serogroup/types
(Ziane et al., 2015).
In this study, meningitis represented 60% of the clinical
presentation of IPD, with 79.2% registered in children younger
than 2 years old. Pleuropneumonia was reported in 22.5% of
the total IPD cases, with the majority being manifested in
infants (88.8%, 16/18). Differently from bacteremia, mastoiditis,
and abdominal infections, the bone and joint infections were
noted exclusively in infants with up to 1 year old. Indeed, IPD
occurs mostly in children under the age of 5 years, especially
within the subgroup of those under 2 years of age (Tan, 2012).
The prevalence of S. pneumoniae carriage in healthy children
younger than 5 years old can fluctuate between 20 and 93.4%
in low income countries, being superior than what is stated
for lower-middle income countries (from 6.5 to 69.8%), as
reported by Adegbola et al. (2014). In addition, the density
of pneumococcal nasopharyngeal carriage seems to decrease in
higher age groups, with the children being more competent
than adults in the transmission of pneumococci (Roca et al.,
2012).
Mortality rate of pneumococcal invasive diseases may range
from 10 to 30%, according with the studies of Pebody et al. (2006),
and Bravo (2009). Although it has been reported that the highest
S. pneumoniae-associated morbidity and mortality rates are in
Africa and Asia (Johnson et al., 2010; Turner et al., 2011), in our
study the case fatality was 8.8%, mainly comprising meningitis
related with vaccine serotypes (85.7%).
Overall, we identified serogroups 14, 19, 23, and 6 as the most
common among IPD and nasopharyngeal carriers (Figure 2).
Frontiers in Microbiology | www.frontiersin.org 7 June 2016 | Volume 7 | Article 803
Ziane et al. S. pneumoniae Isolates from Algeria, in a Pre-vaccination Period
TABLE 2 | Antibiotic susceptibility of 72 isolates of vaccine serotypesa, according to site infection.
Antibioticb, c site of infection Antibiotic susceptibility (%) Total no. of isolates (n = 72) Breakpointb, c (CLSI, 2014)
S I R IR S≤ R≥
PENICILLIN G
Meningitis 33.3 – 66.7 66.7 39 0.06 0.12
PARENTERAL PENICILLIN PG
No meningitis 88.0 8.0 4.0 12.0 25 2 8
ORAL PENICILLIN
No meningitis 20.0 32.0 48.0 80.0 25 0.06 2
AMOXICILLIN
No meningitis 86.4 9.1 4.5 13.6 22 2 8
CEFOTAXIME
Meningitis 59.5 40.5 0.0 40.5 37 0.5 2
No meningitis 91.7 8.3 0.0 8.3 24 1 4
IMIPENEM
Meningitis 56.8 37.8 5.4 43.2 37 0.12 1
ERYTHROMYCIN
Meningitis 57.5 0.0 42.5 42.5 40 ≥21 ≤15
No meningitis 25.9 0.0 74.1 74.1 27 ≥21 ≤15
CLINDAMYCIN
Meningitis 60.0 0.0 40.0 40.0 40 ≥19 ≤15
No meningitis 33.3 0.0 66.7 66.7 27 ≥19 ≤15
CO-TRIMOXAZOLE
Meningitis 46.2 2.6 51.2 53.8 39 ≥19 ≤15
No meningitis 25.0 0.0 75.0 75.0 24 ≥19 ≤15
TETRACYCLINE
Meningitis 71.8 2.6 25.6 27.2 39 ≥28 ≤24
No meningitis 57.7 3.8 42.3 46.2 26 ≥28 ≤24
a Includes serogroups/types: 1 (n = 6), 3 (n = 3), 5 (n = 6), 6B (n = 6), 7 (n = 1), 14 (n = 26), 18C (n = 1), 19A (n = 12), 19F (n = 8), and 23F (n = 3).
bSusceptibility testing by E-test method (MIC determination), for penicillin, amoxicillin, cefotaxime, and imipenem.
cSusceptibility testing by agar disk diffusion method, for erythromycin, clindamycin, co-trimoxazole, tetracycline.
S, Susceptible; I, Intermediate; R, resistant; IR, non-susceptible.
Among IPD isolates, serotypes 14, 19A, 19F, 6B, 1, and 5
were the most frequent, which shows some differences from
data described for other periods in Algeria. For instance, the
serogroups/types 1 and 5 were the most common for the
period of 1996–2000 (Ramdani-Bouguessa and Rahal, 2003), the
serogroups/types 14, 19F, 23F, and 6B for the periods of 2001–
2010 and 2005–2011 (Tali-Maamar et al., 2012; Hecini-Hannachi
et al., 2014), and serogroups/types 14, 19F, 6B, 1, and 19A
for the period of 2005–2012 (Ramdani-Bouguessa et al., 2015).
In Tunisia, the most prevalent serogroups for IPD in children
were nearly the same: 19, 14, 23, and 4 (Charfi et al., 2012).
Internationally, among the 98 known pneumococcal serotypes 11
of them account for more than 70% of IPD, in children younger
than 5 years old, with serotypes 1, 5, 6A, 6B, 14, 19F, 23F being
the most common (Johnson et al., 2010). Indeed, it has been
described that a restricted number of serotypes is in the origin
of the majority of the IPD cases worldwide. To summarize, since
the report of the first studies concerning the distribution of IPD
serotypes in Algeria, there was an emergence of serotype 19A,
which is one of most common causes of invasive disease in
developed countries in children (Geno et al., 2015). Furthermore,
the studied isolates expressing serotype 19A were assigned to
ST276 (M. Caniça, personal communication), which is one of the
most predominant sequence-types within this serotype (Reinert
et al., 2010; Ramos et al., 2014).
Some of the S. pneumoniae serotypes are more prone to
successfully colonize the nasopharynx, being in advantage to
cause invasive disease. The carriage of S. pneumoniae may
play an important role in the pathogenesis of IPD and in
the transmission of this bacterium (Roca et al., 2012). Indeed,
vaccination often brings a decrease in the reduction of vaccine
serotype S. pneumoniae isolates, and a raise in carriage of non-
vaccine serotype isolates (Dias and Caniça, 2007).
In this study, it is essential not only to emphasize the
differences in serotype distribution (in IPD and asymptomatic
carriage), but also to consider the presence of non-vaccine types
(such as 15, 35B, and 34), particularly in carriage, despite the
unavailability of pneumococcal vaccines in Algeria (Figure 2).
Thus, when comparing serotype rate for IPD and nasopharyngeal
carriage, serotypes 14, 1, 5, and 19A were more implicated in IPD
than in carriage (p < 0.01), whereas serotype 6A was exclusively
isolated from carriers (p < 0.01; Table 2).
Frontiers in Microbiology | www.frontiersin.org 8 June 2016 | Volume 7 | Article 803
Ziane et al. S. pneumoniae Isolates from Algeria, in a Pre-vaccination Period
Non-typeable isolates by PCR methods should be typed
by Quellung reaction in order to monitor and detect the
emergence of S. pneumoniae serotype variants, and if this test
is negative, the isolates should be sequenced for the cps locus
to characterize variants (Bentley et al., 2006). In fact, the cpsA
gene is common within most encapsulated S. pneumoniae,
being a highly conserved region of the cps locus in all known
pneumococcal cps operons (Bentley et al., 2006; Pai et al., 2006;
Jin et al., 2009). However, the absence of cpsA amplification in the
multiplex PCR scheme has been reported among rough strains,
and pneumococci with mutated capsular genes, or without the
cps locus (Pai et al., 2006; Ahn et al., 2012; Richter et al., 2013).
Previous studies have also reported absence of cpsA gene by
PCR-based serotyping of S. pneumoniae in 1–3% of the cases,
particularly among serotypes 38 and 25F (da Gloria Carvalho
et al., 2010; Jourdain et al., 2011). In this study, 4.1% of the isolates
lacked the cpsA gene.
Among the cpsA negative isolates, the detection of the lytA
gene resolved the S. pneumoniae specie (Moreno et al., 2005).
Thus, we propose the scheme in Figure 1 for pneumococcal
serotyping that will extend the application of multiplex PCR in
laboratories, and concentrate the use of conventional method in
reference laboratories only.
Similarly to other countries (Flasche et al., 2011; Ahn et al.,
2012; Steens et al., 2013; von Gottberg et al., 2014), we noticed in
Algeria an increase of serotypes covered by the different PCVs,
particularly among IPD (Figure 4). These new data suggests an
increase in the frequency of serotypes included in PCV13 in
Algeria, in comparison with the 74.2% registered between 2005
and 2011 (Hecini-Hannachi et al., 2014), but similar to what was
observed from 2005 to June 2012 (86.8%; Ramdani-Bouguessa
et al., 2015).
Concerning the antibiotic resistance of S. pneumoniae from
vaccine serotypes, the rates obtained were higher in nomeningitis
infections probably due to the large use of these antibiotics in
the treatment of respiratory or urinary tract infections in Algeria.
Tetracycline resistance rate might be explained by a lesser use of
this antibiotic.
Rates of S. pneumoniae non-susceptible to penicillin vary
in the country according to the study periods. Therefore,
Algerian studies reported 34.6% of penicillin non-susceptible
S. pneumoniae in 2003 (Ramdani-Bouguessa and Rahal, 2003),
25.2% in 2001–2010, mostly from meningitis, and 4.4% of high
level resistance to cefotaxime (Tali-Maamar et al., 2012). A later
study, conducted on invasive and non-invasive pneumococcal
disease in children, identified 48% of penicillin non-susceptible
isolates, mainly in no meningeal infections (Ramdani-Bouguessa
et al., 2015). Rates of 48.5% and 45% have been reported in
Morocco and Tunisia, respectively (Charfi et al., 2012; Elmdaghri
et al., 2012).
In our study, the decreased susceptibility to penicillin is
significantly associated with both vaccine serotypes and non-
vaccine serotypes (p < 0.05; data not shown), but the vaccine
serotypes 14, 19A, 19F, and 23F, showed the highest levels of
penicillin resistance (MIC Peni G > 2µg/ml). These data is in
agreement to earlier reports from Algeria (Ramdani-Bouguessa
and Rahal, 2003; Hecini-Hannachi et al., 2014), Tunisia (Charfi
et al., 2012), Morocco, (Elmdaghri et al., 2010), and France
(Varon, 2012), where the serotypes 14, 19F, 23F, 6B were
described as the most resistant. However, in France, after the
introduction of PCV13, the serotypes 19A, 19F, 15A, 35B, and
24F emerged as those with higher resistance (Varon et al.,
2015).
The fluctuations of S. pneumoniae circulating serotypes and
its relation with antibiotic resistance and the PCVs coverage,
reinforces the importance of S. pneumoniae serogroup/type
identification and studies of antibiotic susceptibility, in pre-
and post-vaccination periods, particularly in countries with few
data, such as Algeria. These will help guide the treatment and
will motivate the implementation of strategies for prevention of
pneumococcal disease.
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